It seems pretty obvious that once a company figures out a winning formula, it ought to stick with it.
Acquisitions have definitely done a lot to build and boost specialty pharmaceutical company
Valeant (NYSE:
VRX). Now the company is going to the well again to acquire
Medicis (NYSE:
MRX).
While there's always a risk that Valeant will eventually bite off more
than it can chew, this deal looks like a winner from the get-go.
Read more here:
http://www.investopedia.com/stock-analysis/2012/Valeant-Works-Its-Mojo-With-Medicis-VRX-MRX-AGN-JNJ0907.aspx
No comments:
Post a Comment